Patisiran significantly improves overall health of patients compared to placebo, study finds

today, theof the Peripheral Nerve Association (Peripheral Nerve Society) at
the annual meeting of the company's RNAi therapeutic patisiran therapeutic hereditary ATTR (hATTR) amylodosis clinical phase 3trial(furtheranalysis of the data
) (further analysis of the data)analysis showed that patisiran was able to significantly improve the overallhealth(condition) of the patient compared to placeboPatisiran has beenby the U.SFDA, which has been granted a priority review and the FDA expects to make a decision on its availability by August 11the data released this time is based on a further analysis of the results of a global clinical Phase 3 trial called APOLLO, which includes a placebo-controlled clinical phase 3The main endpoint of the trial was an assessment of the patient's degree of neuropathy after 18 months of treatment through the mNIS-7 scoring systemPatisiran has reached the main end of the experimentresearchers used two different scoring systems, EQ-5D-5L and EQ-VAS, to assess the overall health of patientsEQ-5D-5L was evaluated in the patient's mobility, self-care ability, daily activities, pain/discomfort, and anxiety/depressionThe EQ-VAStest(the patient's overall impression of self-health)18 months after treatment, a larger proportion of patients in the patisiran group had their function in five aspects of the EQ-5D-5L test (shown to be improved or not decreased): activity, 70 percent to 22 percent; self-care, 66 percent vs21 percent; daily activities, 72 percent to 25 percent; pain/discomfort, 73 percent vs31 percent; The EQ-VAS score showed a 2.4-point improvement in the scores of patients treated with patisiran, while the average score for patients in the placebo group decreased by 7.1 points (p0.001
).